Arcalyst (rilonacept) Market Report 2026

Arcalyst (rilonacept) Market Overview

• The Arcalyst (rilonacept) market growth in the historic period has been driven by identification of il 1 driven diseases, limited alternatives for rare inflammatory conditions • Market expansion is supported by growing diagnosis of autoinflammatory syndromes, expansion into additional indications • Growth Driver: Rising Demand For Personalized Medicine Fuels Growth Of The Arcalyst (Rilonacept) Market • Market Trend: Indication Expansion Through IL-1 Trap Therapies Driving Competitive Differentiation In Recurrent Pericarditis Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Arcalyst (rilonacept) Market?

Arcalyst (rilonacept) is a prescription medication classified as an interleukin-1 (IL-1) blocker. It is used to treat certain inflammatory conditions caused by overproduction of interleukin-1, a protein that plays a key role in the body's inflammatory response. Rilonacept works by binding to interleukin-1 alpha and beta, preventing them from interacting with their receptors. This reduces inflammation and helps alleviate symptoms associated with the underlying conditions. The main types of arcalyst (rilonacept) are lyophilized and liquid. Lyophilized Arcalyst (rilonacept) is a freeze-dried formulation of rilonacept designed for reconstitution prior to administration. The various indication involved are cryopyrin-associated periodic syndromes (CAPS), deficiency of interleukin-1 receptor antagonist (DIRA), and other indications. It is distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies and is used by both adult patients and pediatric patients.

What Is The Arcalyst (rilonacept) Market Growth Forecast?

The arcalyst (rilonacept) market size is expected to see strong growth in the next few years. It will grow to $0.33 million in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to growing diagnosis of autoinflammatory syndromes, expansion into additional indications, improved genetic screening, increased biologic therapy accessibility, rising investment in rare disease treatments. Major trends in the forecast period include rising adoption of il 1 blocking therapies, growing use in rare autoinflammatory disorders, expansion of long term inflammation control treatments, increased focus on targeted cytokine inhibition, improved disease management for chronic inflammatory conditions.

Global Arcalyst (rilonacept) Market Segmentation

1) By Type: Lyophilized, Liquid 2) By Indication: Cryopyrin-Associated Periodic Syndromes (CAPS), Deficiency Of Interleukin-1 Receptor Antagonist (DIRA), Other Indications 3) By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End User: Adult Patients, Pediatric Patients

What Is The Driver Of The Arcalyst (rilonacept) Market?

The growing demand for personalized medicines is expected to drive the growth of the arcalyst (rilonacept) market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare decisions to the individual characteristics, such as genetics, environment, and lifestyle, of each patient. The demand for personalized medicine is rising due to its potential to improve treatment effectiveness, reduce adverse effects, and address individual variability in disease progression and drug response. As personalized medicine becomes more common, there is greater awareness and better diagnostic tools available to identify rare and genetically driven conditions. This leads to more people being diagnosed with conditions that Arcalyst can treat, resulting in an increase in demand for the drug. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, a notable rise from the six approvals recorded in 2022. Additionally, in February 2023, according to PMC, the FDA approved 12 new personalized medicines in 2022, marking the eighth consecutive year where personalized medicines comprised at least a quarter of all new drug approvals. Therefore, the growing demand for personalized medicines is driving the growth of the arcalyst (rilonacept) industry.

Key Players In The Global Arcalyst (rilonacept) Market

Major companies operating in the arcalyst (rilonacept) market are Regeneron Pharmaceuticals Inc., Kiniksa Pharmaceuticals Ltd.

Global Arcalyst (rilonacept) Market Trends and Insights

Major companies operating in the Arcalyst (rilonacept) market are focusing on indication expansion, such as interleukin 1 trap therapy for recurrent pericarditis, to gain a competitive advantage. Interleukin-1 trap therapy is a treatment that blocks excess IL-1 proteins to reduce harmful inflammation in the body. For instance, in May 2024, Kiniksa Pharmaceuticals, a US based biopharmaceutical company, received FDA approval for Arcalyst in recurrent pericarditis, featuring weekly subcutaneous dosing, dual IL 1α/IL 1β blockade, and a favorable safety profile in long term use. This expansion broadens Arcalyst’s addressable patient population beyond its original Cryopyrin-Associated Periodic Syndromes (CAPS) indication. However, broader use may expose the drug to increased competition, long-term safety monitoring, and payor scrutiny.

What Are Latest Mergers And Acquisitions In The Arcalyst (rilonacept) Market?

In August 2023, Fairmount Funds Management LLC, a South Philadelphia-based investment firm, acquired a stake in Kiniksa Pharmaceuticals for an undisclosed amount. This strategic move aligns with Fairmount's broader investment strategy focused on long-term value generation within the biotechnology sector. Kiniksa Pharmaceuticals is a Bermuda-based manufacturer of Arcalyst (rilonacept).

Regional Insights

North America was the largest region in the arcalyst (rilonacept) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Arcalyst (rilonacept) Market?

The arcalyst (rilonacept) market consists of monoclonal antibodies, anti-inflammatory drugs, rare disease drugs and other related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Arcalyst (rilonacept) Market Report 2026?

The arcalyst (rilonacept) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the arcalyst (rilonacept) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.